DiBlasi Lab
Inhaled Medical Aerosols and Respiratory Therapeutic Interventions to Promote Neonatal and Pediatric Lung Health
The DiBlasi Lab aims to develop and evaluate inhaled therapies and life-support systems for newborns and children with life-threatening respiratory failure.
Working with worldwide collaborators, industry partners and clinical staff at Seattle Children's Hospital, the lab conducts innovative pre-clinical research to investigate respiratory therapies and devices' therapeutic benefits and responses to promote gas exchange, lung health, growth and development.
The lab focuses on novel drug delivery formulations and devices for administering inhaled medical aerosols and specialty gases, improving airway secretion clearance and optimizing mechanical ventilation.
Laboratory findings have been translated into clinical trials and resulted in several devices and therapies that are currently being used clinically in children. Ultimately, we aim to improve respiratory care for children in all low- and well-resourced clinical settings.
Robert DiBlasi, RRT-NPS, FAARC
Rob DiBlasi, RRT-NPS, FAARC, is the manager of Research and Evidence-Based Practice in the Respiratory Therapy department at Seattle Children's Hospital and principal investigator for the DiBlasi Lab in the Center for Respiratory Biology and Therapeutics (CRBT) at Seattle Children’s Research Institute. He has served as a respiratory therapist at Seattle Children's Hospital for 25 years and as a researcher since 2006. DiBlasi is a board-certified registered respiratory therapist and neonatal/pediatric specialist, and a fellow of the American Association for Respiratory Care.
-
Hattie KenKnight
Research Scientist II
Hattie KenKnight is a research associate of the DiBlasi Lab with a background in biological research and clinical patient care.
-
Ashwitha Legala
Research Scientist II